Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review

Abstract excerpt

Schizophrenia (SCZ) is a severe mental disorder with high morbidity and lifetime disability rates. Patients with SCZ have a higher risk of developing metabolic comorbidities such as obesity and diabetes mellitus, leading to increased mortality. Antipsychotics (APs), which are the mainstay in the treatment of SCZ, increase the risk of these metabolic perturbations. Despite extensive research, the mechanism...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gastrointestinal motility and disorders
• Share to Gut microbiota and health
• Share to Tryptophan and brain disorders